Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Angevin

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Cancer|September 4, 1995
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivoF Farace, E Angevin, P Y Dietrich, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 6, 2000
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12)M Merad, E Angevin, J Wolfers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1995
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancerE Angevin, D Valteau-Couanet, F Farace, et al.
Bone Marrow Transplantation|July 31, 2001
In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and childrenD Valteau-Couanet, E Angevin, C Leboulaire, et al.
Blood|April 26, 2000
Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomasN Guerra, M Guillard, E Angevin, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1994
T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapyE Savelieva, F Farace, E Angevin, et al.
International Journal of Cancer|June 11, 1997
T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccinesF Farace, E Angevin, I Poullion, et al.
Cancer Research|April 20, 2001
Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor functionA Gati, N Guerra, J Giron-Michel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2001
Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cellsI Motta, F André, A Lim, et al.
International Journal of Cancer|July 9, 1993
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinomaF Farace, E Angevin, B Escudier, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|September 4, 1995
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivoF Farace, E Angevin, P Y Dietrich, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 6, 2000
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12)M Merad, E Angevin, J Wolfers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1995
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancerE Angevin, D Valteau-Couanet, F Farace, et al.
Bone Marrow Transplantation|July 31, 2001
In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and childrenD Valteau-Couanet, E Angevin, C Leboulaire, et al.
Blood|April 26, 2000
Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomasN Guerra, M Guillard, E Angevin, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1994
T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapyE Savelieva, F Farace, E Angevin, et al.
International Journal of Cancer|June 11, 1997
T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccinesF Farace, E Angevin, I Poullion, et al.
Cancer Research|April 20, 2001
Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor functionA Gati, N Guerra, J Giron-Michel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2001
Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cellsI Motta, F André, A Lim, et al.
International Journal of Cancer|July 9, 1993
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinomaF Farace, E Angevin, B Escudier, et al.
Pageof 6